Publications by authors named "E M Wachman"

Objectives: Sudden unexpected infant death (SUID) occurs disproportionately among opioid exposed newborns (OENs) compared to those unexposed. The extent that primary caregivers of OENs adhere to SUID-reducing infant care practices is unknown. We examined rates of SUID-reducing practices (smoking cessation, breastfeeding, and safe sleep [supine sleep, room-sharing not bed-sharing, nonuse of soft bedding or objects]) in a pilot sample of caregivers of OENs.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzed medication patterns for opioid use disorder (MOUDs) during pregnancies among a cohort of 3,911 expectant mothers with opioid use disorder (OUD) from seven clinical sites.
  • It found that over 90% of pregnancies involving methadone were among publicly insured individuals, and there was an increasing usage of buprenorphine with naloxone and naltrexone in recent years.
  • The research highlighted that most prenatal care and MOUD documentation occurred within the same trimester, but discontinuity in MOUD treatments across trimesters still existed, indicating a need for improved access to care during pregnancy.
View Article and Find Full Text PDF

Introduction: As perinatal drug overdoses continue to rise, reliable approaches are needed to monitor overdose trends during pregnancy and postpartum. This analysis aimed to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ICD-9/10-CM codes for drug overdose events among people in the MATernaL and Infant clinical NetworK (MAT-LINK) with medication for opioid use disorder (MOUD) during pregnancy.

Methods: People included in this analysis had electronic health record (EHR) documentation of MOUD and a known pregnancy outcome from January 1, 2014 through August 31, 2021.

View Article and Find Full Text PDF

Neonatal Abstinence Syndrome (NAS) after in-utero exposure to opioids remains a significant public health concern. NAS is a highly variable condition in which presentation and severity cannot be explained by clinical factors alone. Research in human subjects has identified both genetic and epigenetic associations with prenatal opioid exposure and NAS severity, including single nucleotide polymorphisms, DNA methylation differences, and gene expression modifications.

View Article and Find Full Text PDF

Concomitant with the opioid epidemic, there has been a rise in pregnant women diagnosed with opioid use disorder and cases of infants born with neonatal opioid withdrawal syndrome (NOWS). NOWS refers to signs and symptoms following cessation of prenatal opioid exposure that comprise neurological, gastrointestinal, and autonomic system dysfunction. A critical indicator of NOWS severity is excessive, high-pitched crying.

View Article and Find Full Text PDF